generic

Paying through the nose

Last month we heard the unedifying news that pharmaceutical companies were ripping off the NHS by charging inflated prices for generic medicines. The practice was first revealed in June 2016 by The Times, but it took a further six months for the Competition and Markets Authority (CMA) to announce its decision to fine Pfizer a record £84.2m and Flynn Pharma an additional £5.2m for charging “excessive and unfair prices” for phenytoin capsules.

It seems incredible that generic medicines can be priced at levels many times higher than the cost of the original branded product.

The price is not always right

Victoria Goldman provides an update on the latest news from the generics market

The price is not always right

Victoria Goldman provides an update on the latest news from the generics market

Paying through the nose

Last month we heard the unedifying news that pharmaceutical companies were ripping off the NHS by charging inflated prices for generic medicines. The practice was first revealed in June 2016 by The Times, but it took a further six months for the Competition and Markets Authority (CMA) to announce its decision to fine Pfizer a record £84.2m and Flynn Pharma an additional £5.2m for charging “excessive and unfair prices” for phenytoin capsules.

It seems incredible that generic medicines can be priced at levels many times higher than the cost of the original branded product.

Accord seals £603m Actavis takeover

Purchase of Actavis from Teva enhances Accord's presence in the UK

Accord seals £603m Actavis takeover

Purchase of Actavis from Teva enhances Accord's presence in the UK

Kim Innes appointed Teva UK general manager

Kim Innes appointed as Teva UK's general manager for the UK and Ireland

Teva completes Actavis takeover

Teva  announces completion of its acquisition of Allergan’s generics business ('Actavis Generics').